Baybay的个人主页 - 老虎社区

Baybay

Baybay

暂无个人介绍

IP属地：未知

145关注

14粉丝

0主题

0勋章

2021-12-07

yes

Wall Street regains some ground with help from easing virus fears

2021-12-07

oh wow like and share please

Mixing Covid Vaccines Is Effective in Study on Pfizer, Astra

2021-12-07

Like please

Brokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth

2021-12-07

okay buybuybuy

Lucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581843817959377,"uuid":"3581843817959377","gmtCreate":1618750321142,"gmtModify":1620018521723,"name":"Baybay","pinyin":"baybay","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":145,"tweetSize":100,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":606888629,"gmtCreate":1638856059365,"gmtModify":1638856059525,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606888629","repostId":"2189686612","repostType":4,"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606883217,"gmtCreate":1638855751452,"gmtModify":1638855751647,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606883217","repostId":"1120108020","repostType":4,"repost":{"id":"1120108020","pubTimestamp":1638855473,"share":"https://www.laohu8.com/m/news/1120108020?lang=&edition=full","pubTime":"2021-12-07 13:37","market":"us","language":"en","title":"Brokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1120108020","media":"Businesstimes","summary":"MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely conti","content":"<div>\n<p>MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth><strong>Businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"5DD.SI":"微机械"},"source_url":"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120108020","content_text":"MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe research team initiated coverage on the company with a \"buy\" call and target price of S$4.05, which is based on its estimated FY2022 earnings per share of S$0.1446, and its estimated FY2022 price-to-earnings ratio of 28 times.\nShares of Micro-Mechanics, a manufacturer of high-precision tools and parts used in the semiconductor industry, were trading at S$3.26 as at the midday break on Dec 7, up S$0.09 or 2.8 per cent.\nAnalyst Ling Lee Keng said the semiconductor supercycle has not peaked yet, and expects global chip sales will grow around 9 per cent in 2022, while the industry will likely post a compound annual growth rate of 5 per cent from 2023 to 2025.\nThis should continue to drive Micro-Mechanics' share price and revenue, which are positively correlated with the semiconductor industry, Ling said.\nGiven the company's range of product offerings across front and back-end processes, it is also well-positioned to gain from growth trends across the wafer fab, assembly and packaging, and semiconductor test equipment segments.\nFurthermore, Micro-Mechanics may be less susceptible to industry swings, since the consumable nature of its back-end tools and front-end equipment parts can support regular demand during most downturn periods.\nThe company also has zero debt and sustainability dividend yields, which helps it to weather cyclical downturns more effectively. Ling expects the company can generate steady dividend payouts given its strong cash flows and balance sheets, with an estimated yield of 4.1 per cent for FY2022 and FY2023.\nAdditionally, although Micro-Mechanics typically trades at a premium above its local peers, it has little to no peers that are directly comparable in terms of product range, scale and geographical coverage, and its share price is also largely aligned with the global average.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606889742,"gmtCreate":1638855569888,"gmtModify":1638855570054,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"okay buybuybuy","listText":"okay buybuybuy","text":"okay buybuybuy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606889742","repostId":"1186153909","repostType":4,"repost":{"id":"1186153909","pubTimestamp":1638854782,"share":"https://www.laohu8.com/m/news/1186153909?lang=&edition=full","pubTime":"2021-12-07 13:26","market":"us","language":"en","title":"Lucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1186153909","media":"Motley Fool","summary":"In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdo","content":"<p>In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.</p>\n<p></p>\n<p>Lucid Group (NASDAQ:LCID) and Nio (NYSE:NIO) are two very different electric vehicle (EV) companies that are looking to make names for themselves on the global stage. Despite their potential, however, both companies are seeing their share prices sink. Let's determine if now is the right time to buy Lucid and Nio, or if investors should run for the exits.</p>\n<p><b>This wild ride is showing no signs of slowing down</b></p>\n<p>Daniel Foelber (Lucid): Lucid had a banner year in 2021. It began mass production and deliveries of its Lucid Air Dream Edition sedan, was named the MotorTrend 2022 Car of the Year, and crushed range ratings by the Environmental Protection Agency (EPA). As a result, investors piled into its stock, which is up over three-fold for the year.</p>\n<p></p>\n<p>However, even Lucid is showing signs that it's cooling off. The stock is now down around 30% from its high, in lockstep with the broader EV industry. Lucid's success in 2022 and beyond depends on a lot of things going right. It needs to increase its manufacturing capacity, produce and deliver an average of 55 cars per day, expand its product line, and develop its Gravity SUV -- and most importantly, fend off the swath of legacy automakers and new players that are champing at the bit to develop their own battery technology. It's a tall order, but Lucid has so far proven an ability to deliver on its promises.</p>\n<p></p>\n<p>As impressive as Lucid's year has been, the reality is that the company is incredibly young and has yet to build the track record necessary to fend off skepticism. Referring to the chart above, it's clear to see that Lucid stock was initially met with euphoria and optimism before undergoing a roughly six-month period in the doldrums.</p>\n<p></p>\n<p>Because Lucid doesn't have meaningful financial metrics like revenue and profit, its performance depends on its ability to prove to investors that people want to buy its cars, it can produce the cars they want to buy, and it will sell even more cars in the future. At the end of the day, there are many factors that lie outside of Lucid's control, namely the chip shortage. However, Lucid has an advantage over other automakers: It isn't too reliant on third-party suppliers, because it builds its own battery packs and controls much of its production process.</p>\n<p></p>\n<p><b>Looking at the big picture</b></p>\n<p>Howard Smith (Nio): Shares of Chinese EV maker Nio are down more than 30% year-to-date, and are 50% off January 2021 highs. The company was valued at close to $100 billion at those highs based on its potential and expected continued strong growth in the global electrification of transportation. But a semiconductor chip shortage hit the industry this year, and affected production for many automotive manufacturers.</p>\n<p></p>\n<p>Nio wasn't immune to that, and it contributed to the drop in shares that has the company's market cap now at about $54 billion. That's still richly valued considering the company has yet to be profitable, and a sharp drop in vehicle deliveries in the month of October spooked investors further. But this week, Nio reported its November delivery results, and that drop in valuation may make now a good time to buy Nio shares.</p>\n<p></p>\n<p>Nio reported a monthly record for vehicle deliveries in November. That helps to alleviate concerns over supply constraints, and verifies that much of the dip in October was due to an interruption in production as the company prepared to upgrade its manufacturing lines for higher volume and new products. A look at how Nio's monthly deliveries progressed throughout 2021 shows the growth pattern appears intact.</p>\n<p></p>\n<p>Through November 2021, Nio deliveries have increased more than 120% over the comparable period in 2020. But even the record November figure only represents about half of the production capacity the company is working toward. That expansion is scheduled to be complete in the spring of 2022, and the company believes there's plenty of demand to support that growth. Nio began exporting vehicles for the first time in July 2021 as it set up a presence in Norway. It expects to move into Germany next year too as it also launches several new products.</p>\n<p></p>\n<p>With that bigger-picture perspective, the decrease in the share price seen this year might make now a good time to buy for investors with patience and the appropriate risk tolerance.</p>\n<p></p>\n<p><b>A great industry to invest in</b></p>\n<p>Lucid and Nio are two of the better up-and-coming electric car growth stocks. Both companies have real competitive advantages that could take them far as developed economies transition away from the internal combustion engine to the electric motor. Investors that agree with the long-term thesis of each company could do well to pick up shares on sale, or take a more conservative approach with a basket of EV stocks.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.\n\nLucid Group (NASDAQ:LCID) and Nio (NYSE:...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LCID":"Lucid Group Inc"},"source_url":"https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186153909","content_text":"In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.\n\nLucid Group (NASDAQ:LCID) and Nio (NYSE:NIO) are two very different electric vehicle (EV) companies that are looking to make names for themselves on the global stage. Despite their potential, however, both companies are seeing their share prices sink. Let's determine if now is the right time to buy Lucid and Nio, or if investors should run for the exits.\nThis wild ride is showing no signs of slowing down\nDaniel Foelber (Lucid): Lucid had a banner year in 2021. It began mass production and deliveries of its Lucid Air Dream Edition sedan, was named the MotorTrend 2022 Car of the Year, and crushed range ratings by the Environmental Protection Agency (EPA). As a result, investors piled into its stock, which is up over three-fold for the year.\n\nHowever, even Lucid is showing signs that it's cooling off. The stock is now down around 30% from its high, in lockstep with the broader EV industry. Lucid's success in 2022 and beyond depends on a lot of things going right. It needs to increase its manufacturing capacity, produce and deliver an average of 55 cars per day, expand its product line, and develop its Gravity SUV -- and most importantly, fend off the swath of legacy automakers and new players that are champing at the bit to develop their own battery technology. It's a tall order, but Lucid has so far proven an ability to deliver on its promises.\n\nAs impressive as Lucid's year has been, the reality is that the company is incredibly young and has yet to build the track record necessary to fend off skepticism. Referring to the chart above, it's clear to see that Lucid stock was initially met with euphoria and optimism before undergoing a roughly six-month period in the doldrums.\n\nBecause Lucid doesn't have meaningful financial metrics like revenue and profit, its performance depends on its ability to prove to investors that people want to buy its cars, it can produce the cars they want to buy, and it will sell even more cars in the future. At the end of the day, there are many factors that lie outside of Lucid's control, namely the chip shortage. However, Lucid has an advantage over other automakers: It isn't too reliant on third-party suppliers, because it builds its own battery packs and controls much of its production process.\n\nLooking at the big picture\nHoward Smith (Nio): Shares of Chinese EV maker Nio are down more than 30% year-to-date, and are 50% off January 2021 highs. The company was valued at close to $100 billion at those highs based on its potential and expected continued strong growth in the global electrification of transportation. But a semiconductor chip shortage hit the industry this year, and affected production for many automotive manufacturers.\n\nNio wasn't immune to that, and it contributed to the drop in shares that has the company's market cap now at about $54 billion. That's still richly valued considering the company has yet to be profitable, and a sharp drop in vehicle deliveries in the month of October spooked investors further. But this week, Nio reported its November delivery results, and that drop in valuation may make now a good time to buy Nio shares.\n\nNio reported a monthly record for vehicle deliveries in November. That helps to alleviate concerns over supply constraints, and verifies that much of the dip in October was due to an interruption in production as the company prepared to upgrade its manufacturing lines for higher volume and new products. A look at how Nio's monthly deliveries progressed throughout 2021 shows the growth pattern appears intact.\n\nThrough November 2021, Nio deliveries have increased more than 120% over the comparable period in 2020. But even the record November figure only represents about half of the production capacity the company is working toward. That expansion is scheduled to be complete in the spring of 2022, and the company believes there's plenty of demand to support that growth. Nio began exporting vehicles for the first time in July 2021 as it set up a presence in Norway. It expects to move into Germany next year too as it also launches several new products.\n\nWith that bigger-picture perspective, the decrease in the share price seen this year might make now a good time to buy for investors with patience and the appropriate risk tolerance.\n\nA great industry to invest in\nLucid and Nio are two of the better up-and-coming electric car growth stocks. Both companies have real competitive advantages that could take them far as developed economies transition away from the internal combustion engine to the electric motor. Investors that agree with the long-term thesis of each company could do well to pick up shares on sale, or take a more conservative approach with a basket of EV stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606889417,"gmtCreate":1638855528634,"gmtModify":1638855528833,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"oh wow like and share please","listText":"oh wow like and share please","text":"oh wow like and share please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606889417","repostId":"1100264021","repostType":4,"repost":{"id":"1100264021","pubTimestamp":1638855132,"share":"https://www.laohu8.com/m/news/1100264021?lang=&edition=full","pubTime":"2021-12-07 13:32","market":"us","language":"en","title":"Mixing Covid Vaccines Is Effective in Study on Pfizer, Astra","url":"https://stock-news.laohu8.com/highlight/detail?id=1100264021","media":"Bloomberg","summary":"Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective prote","content":"<p>Mixing other vaccines with those from&nbsp;AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.</p>\n<p>The University of Oxford study, published Monday in the Lancet medical journal, tested vaccine combinations on more than 1,000 volunteers over 50. Some were immunized with a second dose from&nbsp;Moderna Inc.orNovavax Inc.nine weeks after having received a first shot of AstraZeneca or Pfizer.</p>\n<p>Both Moderna and Novavax boosted immunity after the Astra vaccine, compared with a second Astra injection, while only Moderna increased antibodies after Pfizer, compared with the standard two-shot Pfizer schedule. Astra developed its vaccine with Oxford researchers, while Pfizer worked with BioNTech SE.</p>\n<p>The study gives more evidence that vaccine combinations, already used by some governments, are safe and effective. Mixing two different shots would help low- and middle-income countries manage stockpiles and deal with vaccine shortages as the new omicron variant spreads.</p>\n<p>“There’s a great amount of flexibility” with the first two doses, Matthew Snape, an Oxford pediatrics and vaccinology professor leading the study, said at a press briefing. “Especially in low-income countries, that’s very relevant to having a flexible and adaptable immunization program.”</p>\n<p>Mixing vaccines from Astra and Novavax, which is awaiting regulatory approval, boosted antibody levels four times compared with the matching doses schedule. Those shots are also easier to store than those from Moderna and Pfizer.</p>\n<p>The Pfizer-Novavax mix is the only one that didn’t boost immunity when compared with the two-dose Pfizer schedule. However, the resulting antibody levels still meet the virus protection threshold.</p>\n<p>The study also indicated that people who got a second shot of Moderna after Pfizer or AstraZeneca showed more short-lived side effects, the researchers said. This is in line with&nbsp;previous findings&nbsp;suggesting that mixed doses trigger more symptoms such as fatigue and headache.</p>\n<p>Most mixes also generated good T-cell responses, another arm of a person’s immune defense, though the effect of Novavax as a follow-up to Pfizer was weaker than a second Pfizer jab.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mixing Covid Vaccines Is Effective in Study on Pfizer, Astra</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMixing Covid Vaccines Is Effective in Study on Pfizer, Astra\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.\nThe University of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100264021","content_text":"Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.\nThe University of Oxford study, published Monday in the Lancet medical journal, tested vaccine combinations on more than 1,000 volunteers over 50. Some were immunized with a second dose from Moderna Inc.orNovavax Inc.nine weeks after having received a first shot of AstraZeneca or Pfizer.\nBoth Moderna and Novavax boosted immunity after the Astra vaccine, compared with a second Astra injection, while only Moderna increased antibodies after Pfizer, compared with the standard two-shot Pfizer schedule. Astra developed its vaccine with Oxford researchers, while Pfizer worked with BioNTech SE.\nThe study gives more evidence that vaccine combinations, already used by some governments, are safe and effective. Mixing two different shots would help low- and middle-income countries manage stockpiles and deal with vaccine shortages as the new omicron variant spreads.\n“There’s a great amount of flexibility” with the first two doses, Matthew Snape, an Oxford pediatrics and vaccinology professor leading the study, said at a press briefing. “Especially in low-income countries, that’s very relevant to having a flexible and adaptable immunization program.”\nMixing vaccines from Astra and Novavax, which is awaiting regulatory approval, boosted antibody levels four times compared with the matching doses schedule. Those shots are also easier to store than those from Moderna and Pfizer.\nThe Pfizer-Novavax mix is the only one that didn’t boost immunity when compared with the two-dose Pfizer schedule. However, the resulting antibody levels still meet the virus protection threshold.\nThe study also indicated that people who got a second shot of Moderna after Pfizer or AstraZeneca showed more short-lived side effects, the researchers said. This is in line with previous findings suggesting that mixed doses trigger more symptoms such as fatigue and headache.\nMost mixes also generated good T-cell responses, another arm of a person’s immune defense, though the effect of Novavax as a follow-up to Pfizer was weaker than a second Pfizer jab.","news_type":1},"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":606888629,"gmtCreate":1638856059365,"gmtModify":1638856059525,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606888629","repostId":"2189686612","repostType":4,"repost":{"id":"2189686612","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638826608,"share":"https://www.laohu8.com/m/news/2189686612?lang=&edition=full","pubTime":"2021-12-07 05:36","market":"us","language":"en","title":"Wall Street regains some ground with help from easing virus fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2189686612","media":"Reuters","summary":"Dec 6  - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminis","content":"<p>Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.</p>\n<p>Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&amp;P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .</p>\n<p>While the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.</p>\n<p>\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.</p>\n<p>Lip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 646.95 points, or 1.87%, to 35,227.03, the S&amp;P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite&nbsp;added 139.68 points, or 0.93%, to 15,225.15.</p>\n<p>The S&amp;P 500 Value Index&nbsp;rose 1.5%, outperforming its growth counterpart , which gained 0.9%.</p>\n<p>The economically sensitive Dow Jones Transportation index&nbsp;outperformed the broader market with a 2.3% gain while the small-cap Russell 2000&nbsp;climbed 2%.</p>\n<p>Wall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.</p>\n<p>The S&amp;P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.</p>\n<p>\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>Still, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.</p>\n<p>The industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&amp;P Airline's index&nbsp;closed up 5.5%.</p>\n<p>Other strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb&nbsp;added 8.5%.</p>\n<p>Big decliners included COVID-19 vaccine makers such as Moderna Inc&nbsp;, down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.</p>\n<p>Nvidia&nbsp;closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.</p>\n<p>Kohl's Corp&nbsp;shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.</p>\n<p>JJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.</p>\n<p>\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 20 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.</p>\n<p>On U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street regains some ground with help from easing virus fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street regains some ground with help from easing virus fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-07 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.</p>\n<p>Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&amp;P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .</p>\n<p>While the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.</p>\n<p>\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.</p>\n<p>Lip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 646.95 points, or 1.87%, to 35,227.03, the S&amp;P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite&nbsp;added 139.68 points, or 0.93%, to 15,225.15.</p>\n<p>The S&amp;P 500 Value Index&nbsp;rose 1.5%, outperforming its growth counterpart , which gained 0.9%.</p>\n<p>The economically sensitive Dow Jones Transportation index&nbsp;outperformed the broader market with a 2.3% gain while the small-cap Russell 2000&nbsp;climbed 2%.</p>\n<p>Wall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.</p>\n<p>The S&amp;P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.</p>\n<p>\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>Still, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.</p>\n<p>The industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&amp;P Airline's index&nbsp;closed up 5.5%.</p>\n<p>Other strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb&nbsp;added 8.5%.</p>\n<p>Big decliners included COVID-19 vaccine makers such as Moderna Inc&nbsp;, down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.</p>\n<p>Nvidia&nbsp;closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.</p>\n<p>Kohl's Corp&nbsp;shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.</p>\n<p>JJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.</p>\n<p>\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 20 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.</p>\n<p>On U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DDM":"道指两倍做多ETF",".SPX":"S&P 500 Index","DXD":"道指两倍做空ETF","QQQ":"纳指100ETF","QLD":"纳指两倍做多ETF","DJX":"1/100道琼斯","DOG":"道指反向ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","UDOW":"道指三倍做多ETF-ProShares","TQQQ":"纳指三倍做多ETF","SDOW":"道指三倍做空ETF-ProShares","QID":"纳指两倍做空ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189686612","content_text":"Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.\nOf Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .\nWhile the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.\n\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.\nLip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.\nThe Dow Jones Industrial Average rose 646.95 points, or 1.87%, to 35,227.03, the S&P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite added 139.68 points, or 0.93%, to 15,225.15.\nThe S&P 500 Value Index rose 1.5%, outperforming its growth counterpart , which gained 0.9%.\nThe economically sensitive Dow Jones Transportation index outperformed the broader market with a 2.3% gain while the small-cap Russell 2000 climbed 2%.\nWall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.\nThe S&P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.\n\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.\nStill, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.\nThe industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&P Airline's index closed up 5.5%.\nOther strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb added 8.5%.\nBig decliners included COVID-19 vaccine makers such as Moderna Inc , down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.\nNvidia closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.\nKohl's Corp shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.\nJJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.\n\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.\nThe S&P 500 posted 20 new 52-week highs and one new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.\nOn U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606889417,"gmtCreate":1638855528634,"gmtModify":1638855528833,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"oh wow like and share please","listText":"oh wow like and share please","text":"oh wow like and share please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606889417","repostId":"1100264021","repostType":4,"repost":{"id":"1100264021","pubTimestamp":1638855132,"share":"https://www.laohu8.com/m/news/1100264021?lang=&edition=full","pubTime":"2021-12-07 13:32","market":"us","language":"en","title":"Mixing Covid Vaccines Is Effective in Study on Pfizer, Astra","url":"https://stock-news.laohu8.com/highlight/detail?id=1100264021","media":"Bloomberg","summary":"Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective prote","content":"<p>Mixing other vaccines with those from&nbsp;AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.</p>\n<p>The University of Oxford study, published Monday in the Lancet medical journal, tested vaccine combinations on more than 1,000 volunteers over 50. Some were immunized with a second dose from&nbsp;Moderna Inc.orNovavax Inc.nine weeks after having received a first shot of AstraZeneca or Pfizer.</p>\n<p>Both Moderna and Novavax boosted immunity after the Astra vaccine, compared with a second Astra injection, while only Moderna increased antibodies after Pfizer, compared with the standard two-shot Pfizer schedule. Astra developed its vaccine with Oxford researchers, while Pfizer worked with BioNTech SE.</p>\n<p>The study gives more evidence that vaccine combinations, already used by some governments, are safe and effective. Mixing two different shots would help low- and middle-income countries manage stockpiles and deal with vaccine shortages as the new omicron variant spreads.</p>\n<p>“There’s a great amount of flexibility” with the first two doses, Matthew Snape, an Oxford pediatrics and vaccinology professor leading the study, said at a press briefing. “Especially in low-income countries, that’s very relevant to having a flexible and adaptable immunization program.”</p>\n<p>Mixing vaccines from Astra and Novavax, which is awaiting regulatory approval, boosted antibody levels four times compared with the matching doses schedule. Those shots are also easier to store than those from Moderna and Pfizer.</p>\n<p>The Pfizer-Novavax mix is the only one that didn’t boost immunity when compared with the two-dose Pfizer schedule. However, the resulting antibody levels still meet the virus protection threshold.</p>\n<p>The study also indicated that people who got a second shot of Moderna after Pfizer or AstraZeneca showed more short-lived side effects, the researchers said. This is in line with&nbsp;previous findings&nbsp;suggesting that mixed doses trigger more symptoms such as fatigue and headache.</p>\n<p>Most mixes also generated good T-cell responses, another arm of a person’s immune defense, though the effect of Novavax as a follow-up to Pfizer was weaker than a second Pfizer jab.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mixing Covid Vaccines Is Effective in Study on Pfizer, Astra</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMixing Covid Vaccines Is Effective in Study on Pfizer, Astra\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.\nThe University of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-06/mixing-covid-vaccines-is-effective-in-study-on-pfizer-astra","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100264021","content_text":"Mixing other vaccines with those from AstraZeneca PlcorPfizer Inc.offers at least as effective protection against Covid-19 as giving two doses of the same shots, a U.K. study found.\nThe University of Oxford study, published Monday in the Lancet medical journal, tested vaccine combinations on more than 1,000 volunteers over 50. Some were immunized with a second dose from Moderna Inc.orNovavax Inc.nine weeks after having received a first shot of AstraZeneca or Pfizer.\nBoth Moderna and Novavax boosted immunity after the Astra vaccine, compared with a second Astra injection, while only Moderna increased antibodies after Pfizer, compared with the standard two-shot Pfizer schedule. Astra developed its vaccine with Oxford researchers, while Pfizer worked with BioNTech SE.\nThe study gives more evidence that vaccine combinations, already used by some governments, are safe and effective. Mixing two different shots would help low- and middle-income countries manage stockpiles and deal with vaccine shortages as the new omicron variant spreads.\n“There’s a great amount of flexibility” with the first two doses, Matthew Snape, an Oxford pediatrics and vaccinology professor leading the study, said at a press briefing. “Especially in low-income countries, that’s very relevant to having a flexible and adaptable immunization program.”\nMixing vaccines from Astra and Novavax, which is awaiting regulatory approval, boosted antibody levels four times compared with the matching doses schedule. Those shots are also easier to store than those from Moderna and Pfizer.\nThe Pfizer-Novavax mix is the only one that didn’t boost immunity when compared with the two-dose Pfizer schedule. However, the resulting antibody levels still meet the virus protection threshold.\nThe study also indicated that people who got a second shot of Moderna after Pfizer or AstraZeneca showed more short-lived side effects, the researchers said. This is in line with previous findings suggesting that mixed doses trigger more symptoms such as fatigue and headache.\nMost mixes also generated good T-cell responses, another arm of a person’s immune defense, though the effect of Novavax as a follow-up to Pfizer was weaker than a second Pfizer jab.","news_type":1},"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606883217,"gmtCreate":1638855751452,"gmtModify":1638855751647,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606883217","repostId":"1120108020","repostType":4,"repost":{"id":"1120108020","pubTimestamp":1638855473,"share":"https://www.laohu8.com/m/news/1120108020?lang=&edition=full","pubTime":"2021-12-07 13:37","market":"us","language":"en","title":"Brokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1120108020","media":"Businesstimes","summary":"MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely conti","content":"<div>\n<p>MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrokers' take: DBS initiates Micro-Mechanics with 'buy' on semiconductor growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth><strong>Businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"5DD.SI":"微机械"},"source_url":"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-initiates-micro-mechanics-with-buy-on-semiconductor-growth","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120108020","content_text":"MICRO-MECHANICS Holdings is a good proxy to the semiconductor revenue cycle, which will likely continue to see growth in 2022, DBS Group Research said in a research note on Tuesday (Dec 7).\nThe research team initiated coverage on the company with a \"buy\" call and target price of S$4.05, which is based on its estimated FY2022 earnings per share of S$0.1446, and its estimated FY2022 price-to-earnings ratio of 28 times.\nShares of Micro-Mechanics, a manufacturer of high-precision tools and parts used in the semiconductor industry, were trading at S$3.26 as at the midday break on Dec 7, up S$0.09 or 2.8 per cent.\nAnalyst Ling Lee Keng said the semiconductor supercycle has not peaked yet, and expects global chip sales will grow around 9 per cent in 2022, while the industry will likely post a compound annual growth rate of 5 per cent from 2023 to 2025.\nThis should continue to drive Micro-Mechanics' share price and revenue, which are positively correlated with the semiconductor industry, Ling said.\nGiven the company's range of product offerings across front and back-end processes, it is also well-positioned to gain from growth trends across the wafer fab, assembly and packaging, and semiconductor test equipment segments.\nFurthermore, Micro-Mechanics may be less susceptible to industry swings, since the consumable nature of its back-end tools and front-end equipment parts can support regular demand during most downturn periods.\nThe company also has zero debt and sustainability dividend yields, which helps it to weather cyclical downturns more effectively. Ling expects the company can generate steady dividend payouts given its strong cash flows and balance sheets, with an estimated yield of 4.1 per cent for FY2022 and FY2023.\nAdditionally, although Micro-Mechanics typically trades at a premium above its local peers, it has little to no peers that are directly comparable in terms of product range, scale and geographical coverage, and its share price is also largely aligned with the global average.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606889742,"gmtCreate":1638855569888,"gmtModify":1638855570054,"author":{"id":"3581843817959377","authorId":"3581843817959377","name":"Baybay","avatar":"https://static.tigerbbs.com/ef7dbc91de3962d76f51a84524d549bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"okay buybuybuy","listText":"okay buybuybuy","text":"okay buybuybuy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606889742","repostId":"1186153909","repostType":4,"repost":{"id":"1186153909","pubTimestamp":1638854782,"share":"https://www.laohu8.com/m/news/1186153909?lang=&edition=full","pubTime":"2021-12-07 13:26","market":"us","language":"en","title":"Lucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1186153909","media":"Motley Fool","summary":"In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdo","content":"<p>In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.</p>\n<p></p>\n<p>Lucid Group (NASDAQ:LCID) and Nio (NYSE:NIO) are two very different electric vehicle (EV) companies that are looking to make names for themselves on the global stage. Despite their potential, however, both companies are seeing their share prices sink. Let's determine if now is the right time to buy Lucid and Nio, or if investors should run for the exits.</p>\n<p><b>This wild ride is showing no signs of slowing down</b></p>\n<p>Daniel Foelber (Lucid): Lucid had a banner year in 2021. It began mass production and deliveries of its Lucid Air Dream Edition sedan, was named the MotorTrend 2022 Car of the Year, and crushed range ratings by the Environmental Protection Agency (EPA). As a result, investors piled into its stock, which is up over three-fold for the year.</p>\n<p></p>\n<p>However, even Lucid is showing signs that it's cooling off. The stock is now down around 30% from its high, in lockstep with the broader EV industry. Lucid's success in 2022 and beyond depends on a lot of things going right. It needs to increase its manufacturing capacity, produce and deliver an average of 55 cars per day, expand its product line, and develop its Gravity SUV -- and most importantly, fend off the swath of legacy automakers and new players that are champing at the bit to develop their own battery technology. It's a tall order, but Lucid has so far proven an ability to deliver on its promises.</p>\n<p></p>\n<p>As impressive as Lucid's year has been, the reality is that the company is incredibly young and has yet to build the track record necessary to fend off skepticism. Referring to the chart above, it's clear to see that Lucid stock was initially met with euphoria and optimism before undergoing a roughly six-month period in the doldrums.</p>\n<p></p>\n<p>Because Lucid doesn't have meaningful financial metrics like revenue and profit, its performance depends on its ability to prove to investors that people want to buy its cars, it can produce the cars they want to buy, and it will sell even more cars in the future. At the end of the day, there are many factors that lie outside of Lucid's control, namely the chip shortage. However, Lucid has an advantage over other automakers: It isn't too reliant on third-party suppliers, because it builds its own battery packs and controls much of its production process.</p>\n<p></p>\n<p><b>Looking at the big picture</b></p>\n<p>Howard Smith (Nio): Shares of Chinese EV maker Nio are down more than 30% year-to-date, and are 50% off January 2021 highs. The company was valued at close to $100 billion at those highs based on its potential and expected continued strong growth in the global electrification of transportation. But a semiconductor chip shortage hit the industry this year, and affected production for many automotive manufacturers.</p>\n<p></p>\n<p>Nio wasn't immune to that, and it contributed to the drop in shares that has the company's market cap now at about $54 billion. That's still richly valued considering the company has yet to be profitable, and a sharp drop in vehicle deliveries in the month of October spooked investors further. But this week, Nio reported its November delivery results, and that drop in valuation may make now a good time to buy Nio shares.</p>\n<p></p>\n<p>Nio reported a monthly record for vehicle deliveries in November. That helps to alleviate concerns over supply constraints, and verifies that much of the dip in October was due to an interruption in production as the company prepared to upgrade its manufacturing lines for higher volume and new products. A look at how Nio's monthly deliveries progressed throughout 2021 shows the growth pattern appears intact.</p>\n<p></p>\n<p>Through November 2021, Nio deliveries have increased more than 120% over the comparable period in 2020. But even the record November figure only represents about half of the production capacity the company is working toward. That expansion is scheduled to be complete in the spring of 2022, and the company believes there's plenty of demand to support that growth. Nio began exporting vehicles for the first time in July 2021 as it set up a presence in Norway. It expects to move into Germany next year too as it also launches several new products.</p>\n<p></p>\n<p>With that bigger-picture perspective, the decrease in the share price seen this year might make now a good time to buy for investors with patience and the appropriate risk tolerance.</p>\n<p></p>\n<p><b>A great industry to invest in</b></p>\n<p>Lucid and Nio are two of the better up-and-coming electric car growth stocks. Both companies have real competitive advantages that could take them far as developed economies transition away from the internal combustion engine to the electric motor. Investors that agree with the long-term thesis of each company could do well to pick up shares on sale, or take a more conservative approach with a basket of EV stocks.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid and Nio Are Down Over 30% From Their Highs. Is it Time to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.\n\nLucid Group (NASDAQ:LCID) and Nio (NYSE:...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LCID":"Lucid Group Inc"},"source_url":"https://www.fool.com/investing/2021/12/06/lucid-and-nio-are-down-over-25-from-their-highs-is/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186153909","content_text":"In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns.\n\nLucid Group (NASDAQ:LCID) and Nio (NYSE:NIO) are two very different electric vehicle (EV) companies that are looking to make names for themselves on the global stage. Despite their potential, however, both companies are seeing their share prices sink. Let's determine if now is the right time to buy Lucid and Nio, or if investors should run for the exits.\nThis wild ride is showing no signs of slowing down\nDaniel Foelber (Lucid): Lucid had a banner year in 2021. It began mass production and deliveries of its Lucid Air Dream Edition sedan, was named the MotorTrend 2022 Car of the Year, and crushed range ratings by the Environmental Protection Agency (EPA). As a result, investors piled into its stock, which is up over three-fold for the year.\n\nHowever, even Lucid is showing signs that it's cooling off. The stock is now down around 30% from its high, in lockstep with the broader EV industry. Lucid's success in 2022 and beyond depends on a lot of things going right. It needs to increase its manufacturing capacity, produce and deliver an average of 55 cars per day, expand its product line, and develop its Gravity SUV -- and most importantly, fend off the swath of legacy automakers and new players that are champing at the bit to develop their own battery technology. It's a tall order, but Lucid has so far proven an ability to deliver on its promises.\n\nAs impressive as Lucid's year has been, the reality is that the company is incredibly young and has yet to build the track record necessary to fend off skepticism. Referring to the chart above, it's clear to see that Lucid stock was initially met with euphoria and optimism before undergoing a roughly six-month period in the doldrums.\n\nBecause Lucid doesn't have meaningful financial metrics like revenue and profit, its performance depends on its ability to prove to investors that people want to buy its cars, it can produce the cars they want to buy, and it will sell even more cars in the future. At the end of the day, there are many factors that lie outside of Lucid's control, namely the chip shortage. However, Lucid has an advantage over other automakers: It isn't too reliant on third-party suppliers, because it builds its own battery packs and controls much of its production process.\n\nLooking at the big picture\nHoward Smith (Nio): Shares of Chinese EV maker Nio are down more than 30% year-to-date, and are 50% off January 2021 highs. The company was valued at close to $100 billion at those highs based on its potential and expected continued strong growth in the global electrification of transportation. But a semiconductor chip shortage hit the industry this year, and affected production for many automotive manufacturers.\n\nNio wasn't immune to that, and it contributed to the drop in shares that has the company's market cap now at about $54 billion. That's still richly valued considering the company has yet to be profitable, and a sharp drop in vehicle deliveries in the month of October spooked investors further. But this week, Nio reported its November delivery results, and that drop in valuation may make now a good time to buy Nio shares.\n\nNio reported a monthly record for vehicle deliveries in November. That helps to alleviate concerns over supply constraints, and verifies that much of the dip in October was due to an interruption in production as the company prepared to upgrade its manufacturing lines for higher volume and new products. A look at how Nio's monthly deliveries progressed throughout 2021 shows the growth pattern appears intact.\n\nThrough November 2021, Nio deliveries have increased more than 120% over the comparable period in 2020. But even the record November figure only represents about half of the production capacity the company is working toward. That expansion is scheduled to be complete in the spring of 2022, and the company believes there's plenty of demand to support that growth. Nio began exporting vehicles for the first time in July 2021 as it set up a presence in Norway. It expects to move into Germany next year too as it also launches several new products.\n\nWith that bigger-picture perspective, the decrease in the share price seen this year might make now a good time to buy for investors with patience and the appropriate risk tolerance.\n\nA great industry to invest in\nLucid and Nio are two of the better up-and-coming electric car growth stocks. Both companies have real competitive advantages that could take them far as developed economies transition away from the internal combustion engine to the electric motor. Investors that agree with the long-term thesis of each company could do well to pick up shares on sale, or take a more conservative approach with a basket of EV stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}